|
|||
Conarex |
What is the medium of administration of the drug? |
advertisement
Here is the some steps to help you to save money on Conarex purchase.
Read drug prescription
It is very important to know about what medicine is given by the doctor, for what condition, and when it needs to be taken in what dose. This information given by the doctor is called Prescription. The patients should be familiar with the medicine prescription, and the details about the medicine before purchasing it and using it. Some medications need not be prescribed by healthcare practitioners and can be purchased and used without prescription by the patients; these are called over-the-counter medications. Read the drug prescription information of Conarex before taking it.
What is Conarex
Conarex is an antifungal medicine.Conarex is used to treat infections caused by Conarex, Conarex can invade any part of the body including the mouth, throat, esophagus, lungs, bladder, genital area, and the blood.
Conarex is also used to prevent fungal infection in people with weak immune systems caused by cancer treatment, bone marrow transplant, or diseases such as AIDS.
Conarex may also be used for purposes not listed in Conarex guide.
Conarex side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:
- headache with chest pain and severe dizziness, fainting, fast or pounding heartbeats;
- fever, chills, body aches, flu symptoms;
- easy bruising or bleeding, unusual weakness;
- seizure ;
- liver problems--nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
- skin rash or skin lesions; or
- severe skin reaction--fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
Common side effects may include:
- stomach pain, diarrhea, upset stomach;
- headache;
- dizziness; or
- changes in your sense of taste.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
advertisement
Conarex dosing
Usual Adult Dose for Vaginal Candidiasis:
150 mg orally as a single doseInfectious Diseases Society of America Recommendations:
-Uncomplicated vaginitis: 150 mg orally as a single dose
-Management of recurrent vulvovaginal candidiasis (after 10 to 14 days induction therapy): 150 mg orally once a week for 6 months
-Complicated vulvovaginal candidiasis: 150 mg orally every 72 hours for 3 doses
US CDC Recommendations:
-Uncomplicated vulvovaginal candidiasis: 150 mg orally as a single dose
-Initial therapy for recurrent vulvovaginal candidiasis: 100 to 200 mg orally every 72 hours for 3 doses
-Maintenance therapy for recurrent vulvovaginal candidiasis: 100 to 200 mg orally once a week for 6 months
-Severe vulvovaginal candidiasis: 150 mg orally every 72 hours for 2 doses
US CDC, National Institutes of Health (NIH), and IDSA Recommendations for HIV-infected Patients:
-Uncomplicated vulvovaginal candidiasis: 150 mg orally as a single dose
-Severe or recurrent vulvovaginal candidiasis: 100 to 200 mg orally once a day for at least 7 days
-Suppressive therapy for vulvovaginal candidiasis: 150 mg orally once a week
Comments:
-Recommended as preferred therapy
-Unless frequent or severe recurrences, suppressive therapy generally not recommended
Usual Adult Dose for Oral Thrush:
Oropharyngeal candidiasis: 200 mg IV or orally on the first day followed by 100 mg IV or orally once a dayDuration of therapy: At least 2 weeks, to reduce the risk of relapse
IDSA Recommendations:
-Moderate to severe oropharyngeal candidiasis: 100 to 200 mg IV or orally once a day for 7 to 14 days
Comments:
-Recommended as primary therapy
US CDC, NIH, and IDSA Recommendations for HIV-infected Patients:
-Initial episodes of oropharyngeal candidiasis: 100 mg orally once a day for 7 to 14 days
-Suppressive therapy for oropharyngeal candidiasis: 100 mg orally once a day or 3 times a week
Comments:
-Recommended as preferred oral therapy
-Unless frequent or severe recurrences, suppressive therapy generally not recommended
Usual Adult Dose for Candidemia:
Doses up to 400 mg/day have been used.Comments:
-Optimal therapeutic dose and therapy duration have not been established.
Use: For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia
IDSA Recommendations:
Candidemia in nonneutropenic or neutropenic patients: 800 mg IV or orally on the first day followed by 400 mg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve
-Neutropenic patients: 2 weeks after Candida cleared from bloodstream and candidemia symptoms and neutropenia resolve
Chronic disseminated candidiasis in stable patients: 400 mg IV or orally once a day
Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression
Candida osteoarticular infection: 400 mg IV or orally once a day
Duration of therapy:
-Osteomyelitis: 6 to 12 months
-Septic arthritis: At least 6 weeks
CNS candidiasis (after initial regimen of IV amphotericin B): 400 to 800 mg IV or orally once a day
Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve
Candida cardiovascular system infection: 400 to 800 mg IV or orally once a day
Duration of therapy:
-Endocarditis: Lifelong suppressive therapy may be indicated.
-Pericarditis or myocarditis: Often several months
-Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared
-Infected pacemaker, implantable cardioverter defibrillator (ICD), or ventricular assist device (VAD): 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed
Comments:
-Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is often appropriate.
-Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill.
-Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis
-Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD
Usual Adult Dose for Fungal Pneumonia:
Doses up to 400 mg/day have been used.Comments:
-Optimal therapeutic dose and therapy duration have not been established.
Use: For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia
IDSA Recommendations:
Candidemia in nonneutropenic or neutropenic patients: 800 mg IV or orally on the first day followed by 400 mg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve
-Neutropenic patients: 2 weeks after Candida cleared from bloodstream (documented) and candidemia symptoms and neutropenia resolve
Chronic disseminated candidiasis in stable patients: 400 mg IV or orally once a day
Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression
Candida osteoarticular infection: 400 mg IV or orally once a day
Duration of therapy:
-Osteomyelitis: 6 to 12 months
-Septic arthritis: At least 6 weeks
CNS candidiasis (after initial regimen of IV amphotericin B): 400 to 800 mg IV or orally once a day
Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve
Candida cardiovascular system infection: 400 to 800 mg IV or orally once a day
Duration of therapy:
-Endocarditis: Lifelong suppressive therapy may be indicated.
-Pericarditis or myocarditis: Often several months
-Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared
-Infected pacemaker, implantable cardioverter defibrillator (ICD), or ventricular assist device (VAD): 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed
Comments:
-Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is often appropriate.
-Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill.
-Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis
-Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD
Usual Adult Dose for Fungal Infection -- Disseminated:
Doses up to 400 mg/day have been used.Comments:
-Optimal therapeutic dose and therapy duration have not been established.
Use: For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia
IDSA Recommendations:
Candidemia in nonneutropenic or neutropenic patients: 800 mg IV or orally on the first day followed by 400 mg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve
-Neutropenic patients: 2 weeks after Candida cleared from bloodstream and candidemia symptoms and neutropenia resolve
Chronic disseminated candidiasis in stable patients: 400 mg IV or orally once a day
Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression
Candida osteoarticular infection: 400 mg IV or orally once a day
Duration of therapy:
-Osteomyelitis: 6 to 12 months
-Septic arthritis: At least 6 weeks
CNS candidiasis (after initial regimen of IV amphotericin B): 400 to 800 mg IV or orally once a day
Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve
Candida cardiovascular system infection: 400 to 800 mg IV or orally once a day
Duration of therapy:
-Endocarditis: Lifelong suppressive therapy may be indicated.
-Pericarditis or myocarditis: Often several months
-Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared
-Infected pacemaker, implantable cardioverter defibrillator (ICD), or ventricular assist device (VAD): 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed
Comments:
-Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is often appropriate.
-Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill.
-Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis
-Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD
Usual Adult Dose for Systemic Candidiasis:
Doses up to 400 mg/day have been used.Comments:
-Optimal therapeutic dose and therapy duration have not been established.
Use: For systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia
IDSA Recommendations:
Candidemia in nonneutropenic or neutropenic patients: 800 mg IV or orally on the first day followed by 400 mg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve
-Neutropenic patients: 2 weeks after Candida cleared from bloodstream (documented) and candidemia symptoms and neutropenia resolve
Chronic disseminated candidiasis in stable patients: 400 mg IV or orally once a day
Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression
Candida osteoarticular infection: 400 mg IV or orally once a day
Duration of therapy:
-Osteomyelitis: 6 to 12 months
-Septic arthritis: At least 6 weeks
CNS candidiasis (after initial regimen of IV amphotericin B): 400 to 800 mg IV or orally once a day
Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve
Candida cardiovascular system infection: 400 to 800 mg IV or orally once a day
Duration of therapy:
-Endocarditis: Lifelong suppressive therapy may be indicated.
-Pericarditis or myocarditis: Often several months
-Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared
-Infected pacemaker, implantable cardioverter defibrillator (ICD), or ventricular assist device (VAD): 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed
Comments:
-Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is often appropriate.
-Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill.
-Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis
-Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD
Usual Adult Dose for Esophageal Candidiasis:
200 mg IV or orally on the first day followed by 100 mg IV or orally once a dayDuration of therapy: At least 3 weeks and for at least 2 weeks after symptoms resolve
Comments:
-Doses up to 400 mg/day may be used based on clinical judgment of patient response.
IDSA Recommendations: 200 to 400 mg IV or orally once a day for 14 to 21 days
Comments:
-Recommended as primary therapy; oral Conarex is preferred.
US CDC, NIH, and IDSA Recommendations for HIV-infected Patients: 100 to 400 mg IV or orally once a day for 14 to 21 days
-Suppressive therapy: 100 to 200 mg orally once a day
Comments:
-Recommended as preferred therapy
-Unless frequent or severe recurrences, suppressive therapy generally not recommended
Usual Adult Dose for Candida Urinary Tract Infection:
50 to 200 mg IV or orally once a dayUse: For the treatment of Candida urinary tract infections and peritonitis
IDSA Recommendations:
-Asymptomatic cystitis in patients undergoing urologic procedures: 200 to 400 mg IV or orally once a day for several days before and after the procedure
-Symptomatic cystitis: 200 mg IV or orally once a day for 2 weeks
-Pyelonephritis: 200 to 400 mg IV or orally once a day for 2 weeks
-Urinary Conarex balls: 200 to 400 mg IV or orally once a day until symptoms resolve and urine cultures clear of Candida
Comments:
-Recommended as primary therapy
-The suggested dose for candidemia is recommended for patients with pyelonephritis and suspected disseminated candidiasis.
-Surgical removal of urinary Conarex balls strongly recommended.
Usual Adult Dose for Fungal Peritonitis:
50 to 200 mg IV or orally once a dayUse: For the treatment of Candida urinary tract infections and peritonitis
IDSA Recommendations:
-Asymptomatic cystitis in patients undergoing urologic procedures: 200 to 400 mg IV or orally once a day for several days before and after the procedure
-Symptomatic cystitis: 200 mg IV or orally once a day for 2 weeks
-Pyelonephritis: 200 to 400 mg IV or orally once a day for 2 weeks
-Urinary Conarex balls: 200 to 400 mg IV or orally once a day until symptoms resolve and urine cultures clear of Candida
Comments:
-Recommended as primary therapy
-The suggested dose for candidemia is recommended for patients with pyelonephritis and suspected disseminated candidiasis.
-Surgical removal of urinary Conarex balls strongly recommended.
Usual Adult Dose for Cryptococcal Meningitis -- Immunocompetent Host:
Acute infection: 400 mg IV or orally on the first day followed by 200 mg IV or orally once a dayDuration of therapy: 10 to 12 weeks after CSF culture is negative
Comments:
-Dose of 400 mg IV or orally once a day may be used based on clinical judgment of patient response.
IDSA Recommendations:
-Consolidation therapy : 400 to 800 mg orally once a day for 8 weeks
-Maintenance therapy: 200 mg orally once a day for 6 to 12 months
Comments:
-Preferred agent
-The higher dose (800 mg/day) is recommended for consolidation therapy if the 2-week induction regimen was used.
-Maintenance therapy is recommended to prevent relapse.
Cerebral cryptococcoma:
-Consolidation and maintenance therapy (after induction therapy): 400 to 800 mg orally once a day for 6 to 18 months
Usual Adult Dose for Cryptococcal Meningitis -- Immunosuppressed Host:
Acute infection: 400 mg IV or orally on the first day followed by 200 mg IV or orally once a dayDuration of therapy: 10 to 12 weeks after CSF culture is negative
Comments:
-Dose of 400 mg IV or orally once a day may be used based on clinical judgment of patient response.
Suppression of relapse in patients with AIDS: 200 mg IV or orally once a day
IDSA Recommendations:
HIV-infected patients:
-Induction therapy: 800 to 2000 mg orally once a day for 6 to 12 weeks, depending on regimen
-Consolidation therapy (after induction therapy): 400 mg orally once a day for at least 8 weeks
-Maintenance (suppressive) and prophylactic therapy: 200 mg orally once a day for at least 12 months
Comments:
-Recommended as an alternative for induction therapy; use is not encouraged.
-Preferred agent for consolidation therapy and maintenance and prophylactic therapy
Organ transplant recipients:
-Consolidation therapy (after induction therapy): 400 to 800 mg orally once a day for 8 weeks
-Maintenance therapy: 200 to 400 mg orally once a day for 6 to 12 months
Comments:
-Preferred agent
Cerebral cryptococcoma:
-Consolidation and maintenance therapy (after induction therapy): 400 to 800 mg orally once a day for 6 to 18 months
US CDC, NIH, and IDSA Recommendations for HIV-infected Patients:
-Induction therapy: 400 to 1200 mg IV or orally once a day for at least 2 weeks
-Consolidation therapy (after at least 2 weeks successful induction therapy): 400 mg IV or orally once a day for at least 8 weeks
-Maintenance therapy: 200 mg orally once a day for at least 1 year
Comments:
-Recommended for use in alternative regimens for induction therapy; dose depends on regimen (i.e., used with amphotericin B, flucytosine, or alone).
-Recommended as preferred regimen for consolidation therapy; should be followed by maintenance therapy
-Recommended as preferred regimen for maintenance therapy
Usual Adult Dose for Cryptococcosis:
IDSA Recommendations:Mild to moderate pulmonary infection and nonmeningeal, nonpulmonary infection if CNS disease ruled out, no fungemia, single site of infection, no immunosuppressive risk factors: 400 mg orally once a day for 6 to 12 months
Severe pulmonary infection and nonmeningeal, nonpulmonary infection with cryptococcemia:
-Consolidation therapy : 400 to 800 mg orally once a day for at least 8 weeks
-Maintenance therapy: 200 to 400 mg orally once a day for 12 months
Comments:
-Preferred agent
-Maintenance therapy is recommended to prevent relapse.
-Primary prophylaxis not routinely recommended.
US CDC, NIH, and IDSA Recommendations for HIV-infected Patients:
Non-CNS cryptococcosis with mild to moderate symptoms and focal pulmonary infiltrates: 400 mg orally once a day for 12 months
Non-CNS, extrapulmonary cryptococcosis and diffuse pulmonary disease:
-Induction therapy: 400 to 1200 mg IV or orally once a day for at least 2 weeks
-Consolidation therapy (after at least 2 weeks successful induction therapy): 400 mg IV or orally once a day for at least 8 weeks
-Maintenance therapy: 200 mg orally once a day for at least 1 year
Comments:
-Recommended for use in alternative regimens for induction therapy; dose depends on regimen (i.e., used with amphotericin B, flucytosine, or alone).
-Recommended as preferred regimen for consolidation therapy; should be followed by maintenance therapy
-Recommended as preferred regimen for maintenance therapy
Usual Adult Dose for Fungal Infection Prophylaxis:
400 mg IV or orally once a dayDuration of therapy: 7 days after neutrophil count rises above 1000 cells/mm3
Comments:
-If severe granulocytopenia (less than 500 neutrophils/mm3) is expected, prophylaxis should start several days before the likely onset of neutropenia.
Use: For prophylaxis to reduce the incidence of candidiasis in bone marrow transplantation recipients who receive cytotoxic chemotherapy and/or radiation therapy
IDSA Recommendations:
Empiric therapy for suspected candidiasis in nonneutropenic or neutropenic patients: 800 mg IV or orally on the first day followed by 400 mg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: Uncertain; should discontinue if cultures and/or serodiagnostic test results negative
Comments:
-Suspected candidiasis in nonneutropenic patients: Recommended as primary therapy; an echinocandin is preferred for moderately severe to severe illness or recent azole exposure; patient selection should be based on clinical risk factors, serologic tests, and culture data.
-Suspected candidiasis in neutropenic patients: Recommended as alternative therapy; should start empiric therapy after 4 days persistent fever despite antibiotics; serodiagnostic and computed tomography (CT) imaging may help; should not use in patients with prior azole prophylaxis.
Usual Adult Dose for Coccidioidomycosis -- Meningitis:
IDSA Recommendations: 400 mg orally once a dayComments:
-Some experts start therapy with 800 to 1000 mg/day.
-Patients who respond to therapy should continue this treatment indefinitely.
US CDC, NIH, and IDSA Recommendations for HIV-infected Patients:
-Meningeal infection: 400 to 800 mg IV or orally once a day
-Chronic suppressive therapy: 400 mg orally once a day
Comments:
-Recommended as preferred therapy for meningeal infection and chronic suppressive therapy
-A specialist should be consulted for meningeal infections.
-Since relapse is common, suppressive therapy should be lifelong.
Usual Adult Dose for Coccidioidomycosis:
IDSA Recommendations: 400 to 800 mg IV or orally once a dayDuration of therapy:
-Uncomplicated coccidioidal pneumonia: 3 to 6 months
-Diffuse pneumonia and chronic progressive fibrocavitary pneumonia: At least 1 year
Comments:
-Therapy for diffuse pneumonia is usually started with high-dose Conarex; if therapy started with IV amphotericin B (e.g., if significant hypoxia or rapid deterioration), may switch to oral azole antifungal therapy after evident improvement; total duration of therapy should be at least 1 year; oral azole therapy should continue as secondary prophylaxis in severely immunodeficient patients.
-Initial therapy with oral azole antifungals is recommended for chronic progressive fibrocavitary pneumonia.
-Initial therapy for nonmeningeal disseminated infection (extrapulmonary) is generally started with oral azole antifungals, most often Conarex or itraconazole; clinical trials used 400 mg/day; some experts recommend up to 2 g/day of Conarex.
US CDC, NIH, and IDSA Recommendations for HIV-infected Patients:
-Primary prophylaxis: 400 mg orally once a day
-Mild infections (e.g., focal pneumonia): 400 mg orally once a day
-Severe nonmeningeal infection (diffuse pulmonary or severely ill patients with extrathoracic disseminated disease) - acute phase: 400 mg IV or orally once a day
-Chronic suppressive therapy (secondary prophylaxis): 400 mg orally once a day
Comments:
-Recommended as preferred therapy for mild infection and chronic suppressive therapy
-Recommended as alternative therapy for severe nonmeningeal infection; some experts add a triazole to amphotericin B (preferred therapy) and continue the triazole after amphotericin B is stopped.
Usual Adult Dose for Histoplasmosis:
IDSA Recommendations:-Disseminated infections in patients without AIDS: 200 to 800 mg IV or orally once a day for at least 12 months
-CNS infection : 200 to 400 mg IV or orally once a day for 12 months
Comments:
-Recommended as alternative therapy in patients unable to use itraconazole
US CDC, NIH, and IDSA Recommendations for HIV-infected Patients:
-Less severe disseminated infection: 800 mg orally once a day for at least 12 months
-Long-term suppressive therapy (secondary prophylaxis): 400 mg orally once a day for more than 1 year
Comments:
-Recommended as alternative therapy
-This drug should only be used for treatment of less severe disseminated infection in moderately ill patients intolerant of itraconazole.
Usual Adult Dose for Blastomycosis:
IDSA Recommendations:-Mild to moderate pulmonary infection or mild to moderate disseminated infection without CNS involvement: 400 to 800 mg orally once a day for at least 6 to 12 months
-CNS infection (after initial regimen of IV amphotericin B): 800 mg orally once a day for at least 12 months and until CSF abnormalities resolve
Comments:
-Recommended as alternative therapy for mild to moderate pulmonary infection or mild to moderate disseminated infection without CNS involvement
-Recommended as follow-up therapy for CNS infection
Usual Adult Dose for Onychomycosis -- Fingernail:
Some experts recommend: 150 to 300 mg orally once a weekDuration of therapy:
-Fingernail infections: 3 to 6 months
-Toenail infections: 6 to 12 months
Usual Adult Dose for Onychomycosis -- Toenail:
Some experts recommend: 150 to 300 mg orally once a weekDuration of therapy:
-Fingernail infections: 3 to 6 months
-Toenail infections: 6 to 12 months
Usual Adult Dose for Sporotrichosis:
IDSA Recommendations:Cutaneous or lymphocutaneous infection: 400 to 800 mg IV or orally once a day
Duration of therapy: 2 to 4 weeks after all lesions resolve
Comments:
-Recommended as alternative therapy; should only be used if other agents are not tolerated
Usual Pediatric Dose for Esophageal Candidiasis:
2 weeks or younger (gestational age 26 to 29 weeks): 3 mg/kg IV or orally every 72 hoursOlder than 2 weeks: 6 mg/kg IV or orally on the first day followed by 3 mg/kg IV or orally once a day
Duration of therapy: At least 3 weeks and for at least 2 weeks after symptoms resolve
Comments:
-Doses up to 12 mg/kg/day may be used in patients older than 2 weeks based on clinical judgment of patient response; this correlates to 12 mg/kg/72 hours in premature newborns during their first 2 weeks of life.
IDSA Recommendations: 3 to 6 mg/kg IV or orally once a day for 14 to 21 days
Comments:
-Recommended as primary therapy; oral Conarex is preferred.
US CDC, NIH, IDSA, Pediatric Infectious Diseases Society (PIDS), and American Academy of Pediatrics (AAP) Recommendations for HIV-exposed and HIV-infected Children: 6 to 12 mg/kg IV or orally once a day
Maximum dose: 600 mg/dose
Duration of therapy: At least 3 weeks and for at least 2 weeks after symptoms resolve
Comments:
-Oral Conarex recommended as preferred therapy; IV dosing recommended as alternative therapy for infants and children of all ages.
-If neonate creatinine level is greater than 1.2 mg/dL for 3 consecutive doses, the dosing interval for the higher dose may be extended to 12 mg/kg every 48 hours until serum creatinine level is less than 1.2 mg/dL.
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents: 100 to 400 mg IV or orally once a day for 14 to 21 days
-Suppressive therapy: 100 to 200 mg orally once a day
Comments:
-Recommended as preferred therapy
-Unless frequent or severe recurrences, suppressive therapy generally not recommended
Usual Pediatric Dose for Oral Thrush:
Oropharyngeal candidiasis:2 weeks or younger : 3 mg/kg IV or orally every 72 hours
Older than 2 weeks: 6 mg/kg IV or orally on the first day followed by 3 mg/kg IV or orally once a day
Duration of therapy: At least 2 weeks, to reduce the risk of relapse
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children: 6 to 12 mg/kg orally once a day
Maximum dose: 400 mg/dose
Duration of therapy: 7 to 14 days
Comments:
-Recommended as preferred therapy; oral Conarex recommended for moderate or severe oropharyngeal candidiasis.
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents:
-Initial episodes: 100 mg orally once a day for 7 to 14 days
-Suppressive therapy: 100 mg orally once a day or 3 times a week
Comments:
-Recommended as preferred oral therapy
-Unless frequent or severe recurrences, suppressive therapy generally not recommended
Usual Pediatric Dose for Candidemia:
2 weeks or younger (gestational age 26 to 29 weeks): 6 to 12 mg/kg IV or orally every 72 hoursOlder than 2 weeks: 6 to 12 mg/kg/day IV or orally
Use: For the treatment of candidemia and disseminated Candida infections
IDSA Recommendations:
Neonatal candidiasis: 12 mg/kg IV or orally once a day for at least 3 weeks
Candidemia in nonneutropenic or neutropenic patients: 12 mg/kg IV or orally on the first day followed by 6 mg/kg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve
-Neutropenic patients: 2 weeks after Candida cleared from bloodstream (documented) and candidemia symptoms and neutropenia resolve
Chronic disseminated candidiasis in stable patients: 6 mg/kg IV or orally once a day
Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression
Candida osteoarticular infection: 6 mg/kg IV or orally once a day
Duration of therapy:
-Osteomyelitis: 6 to 12 months
-Septic arthritis: At least 6 weeks
CNS candidiasis (after initial regimen of IV amphotericin B): 6 to 12 mg/kg IV or orally once a day
Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve
Candida cardiovascular system infection: 6 to 12 mg/kg IV or orally once a day
Duration of therapy:
-Endocarditis: Lifelong suppressive therapy may be indicated.
-Pericarditis or myocarditis: Often several months
-Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared
-Infected pacemaker, ICD, or VAD: 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed
Comments:
-Recommended as primary therapy for neonatal candidiasis
-Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is appropriate in many cases.
-Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill.
-Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis
-Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:
Invasive disease in infants and children (all ages): 12 mg/kg IV once a day
Maximum dose: 600 mg/dose
Duration of therapy: Based on presence of deep-tissue foci and clinical response
-Uncomplicated candidemia: At least 2 weeks after last positive blood culture
Secondary prophylaxis: 3 to 6 mg/kg IV or orally once a day
Maximum dose: 200 mg/dose
Comments:
-Recommended as alternative therapy in critically ill patients with invasive disease
-Recommended as preferred therapy in patients with invasive disease who are not critically ill; this drug should be avoided for Candida krusei and C glabrata.
-Secondary prophylaxis may be considered for frequent or severe recurrences of candidiasis; not routinely recommended.
Usual Pediatric Dose for Fungal Infection -- Disseminated:
2 weeks or younger : 6 to 12 mg/kg IV or orally every 72 hoursOlder than 2 weeks: 6 to 12 mg/kg/day IV or orally
Use: For the treatment of candidemia and disseminated Candida infections
IDSA Recommendations:
Neonatal candidiasis: 12 mg/kg IV or orally once a day for at least 3 weeks
Candidemia in nonneutropenic or neutropenic patients: 12 mg/kg IV or orally on the first day followed by 6 mg/kg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve
-Neutropenic patients: 2 weeks after Candida cleared from bloodstream (documented) and candidemia symptoms and neutropenia resolve
Chronic disseminated candidiasis in stable patients: 6 mg/kg IV or orally once a day
Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression
Candida osteoarticular infection: 6 mg/kg IV or orally once a day
Duration of therapy:
-Osteomyelitis: 6 to 12 months
-Septic arthritis: At least 6 weeks
CNS candidiasis (after initial regimen of IV amphotericin B): 6 to 12 mg/kg IV or orally once a day
Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve
Candida cardiovascular system infection: 6 to 12 mg/kg IV or orally once a day
Duration of therapy:
-Endocarditis: Lifelong suppressive therapy may be indicated.
-Pericarditis or myocarditis: Often several months
-Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared
-Infected pacemaker, ICD, or VAD: 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed
Comments:
-Recommended as primary therapy for neonatal candidiasis
-Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is appropriate in many cases.
-Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill.
-Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis
-Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:
Invasive disease in infants and children (all ages): 12 mg/kg IV once a day
Maximum dose: 600 mg/dose
Duration of therapy: Based on presence of deep-tissue foci and clinical response
-Uncomplicated candidemia: At least 2 weeks after last positive blood culture
Secondary prophylaxis: 3 to 6 mg/kg IV or orally once a day
Maximum dose: 200 mg/dose
Comments:
-Recommended as alternative therapy in critically ill patients with invasive disease
-Recommended as preferred therapy in patients with invasive disease who are not critically ill; this drug should be avoided for Candida krusei and C glabrata.
-Secondary prophylaxis may be considered for frequent or severe recurrences of candidiasis; not routinely recommended.
Usual Pediatric Dose for Systemic Candidiasis:
2 weeks or younger (gestational age 26 to 29 weeks): 6 to 12 mg/kg IV or orally every 72 hoursOlder than 2 weeks: 6 to 12 mg/kg/day IV or orally
Use: For the treatment of candidemia and disseminated Candida infections
IDSA Recommendations:
Neonatal candidiasis: 12 mg/kg IV or orally once a day for at least 3 weeks
Candidemia in nonneutropenic or neutropenic patients: 12 mg/kg IV or orally on the first day followed by 6 mg/kg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: 14 days after first negative blood culture and candidemia signs/symptoms resolve
-Neutropenic patients: 2 weeks after Candida cleared from bloodstream (documented) and candidemia symptoms and neutropenia resolve
Chronic disseminated candidiasis in stable patients: 6 mg/kg IV or orally once a day
Duration of therapy: Until lesions have resolved (usually months) and through periods of immunosuppression
Candida osteoarticular infection: 6 mg/kg IV or orally once a day
Duration of therapy:
-Osteomyelitis: 6 to 12 months
-Septic arthritis: At least 6 weeks
CNS candidiasis (after initial regimen of IV amphotericin B): 6 to 12 mg/kg IV or orally once a day
Duration of therapy: Until all signs/symptoms and CSF and radiologic abnormalities resolve
Candida cardiovascular system infection: 6 to 12 mg/kg IV or orally once a day
Duration of therapy:
-Endocarditis: Lifelong suppressive therapy may be indicated.
-Pericarditis or myocarditis: Often several months
-Suppurative thrombophlebitis: At least 2 weeks after candidemia cleared
-Infected pacemaker, ICD, or VAD: 4 to 6 weeks after device removed; chronic suppressive therapy if VAD not removed
Comments:
-Recommended as primary therapy for neonatal candidiasis
-Candidemia in nonneutropenic patients: Recommended as primary therapy; an echinocandin is recommended for moderately severe to severe illness or recent azole exposure; switching to this drug after initial echinocandin is appropriate in many cases.
-Candidemia in neutropenic patients: Recommended as alternative therapy; an echinocandin or IV amphotericin B preferred for most patients; this drug recommended for patients without recent azole exposure and who are not critically ill.
-Recommended as primary therapy for chronic disseminated candidiasis in stable patients, Candida osteoarticular infection, CNS candidiasis, pericarditis/myocarditis, and suppurative thrombophlebitis
-Recommended as alternative therapy for endocarditis and infected pacemaker, ICD, or VAD
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:
Invasive disease in infants and children (all ages): 12 mg/kg IV once a day
Maximum dose: 600 mg/dose
Duration of therapy: Based on presence of deep-tissue foci and clinical response
-Uncomplicated candidemia: At least 2 weeks after last positive blood culture
Secondary prophylaxis: 3 to 6 mg/kg IV or orally once a day
Maximum dose: 200 mg/dose
Comments:
-Recommended as alternative therapy in critically ill patients with invasive disease
-Recommended as preferred therapy in patients with invasive disease who are not critically ill; this drug should be avoided for Candida krusei and C glabrata.
-Secondary prophylaxis may be considered for frequent or severe recurrences of candidiasis; not routinely recommended.
Usual Pediatric Dose for Cryptococcal Meningitis -- Immunocompetent Host:
Acute infection:2 weeks or younger : 6 mg/kg IV or orally every 72 hours
Older than 2 weeks: 12 mg/kg IV or orally on the first day followed by 6 mg/kg IV or orally once a day
Duration of therapy: 10 to 12 weeks after CSF culture is negative
Comments:
-Dose of 12 mg/kg IV or orally once a day may be used in patients older than 2 weeks based on clinical judgment of patient response; this correlates to 12 mg/kg IV or orally every 72 hours in premature newborns during their first 2 weeks of life.
IDSA Recommendations:
CNS infection in children:
-Consolidation therapy (after induction therapy): 10 to 12 mg/kg orally once a day for 8 weeks
-Maintenance therapy: 6 mg/kg orally once a day
Comments:
-Preferred agent
-Maintenance therapy is recommended to prevent relapse.
Usual Pediatric Dose for Cryptococcal Meningitis -- Immunosuppressed Host:
Acute infection:2 weeks or younger (gestational age 26 to 29 weeks): 6 mg/kg IV or orally every 72 hours
Older than 2 weeks: 12 mg/kg IV or orally on the first day followed by 6 mg/kg IV or orally once a day
Duration of therapy: 10 to 12 weeks after CSF culture is negative
Comments:
-Dose of 12 mg/kg IV or orally once a day may be used in patients older than 2 weeks based on clinical judgment of patient response; this correlates to 12 mg/kg IV or orally every 72 hours in premature newborns during their first 2 weeks of life.
Suppression of relapse in children with AIDS: 6 mg/kg IV or orally once a day
IDSA Recommendations for children:
CNS disease:
-Consolidation therapy (after induction therapy): 10 to 12 mg/kg/day orally in 2 divided doses for 8 weeks
-Maintenance therapy in HIV-infected patients: 6 mg/kg orally once a day
Comments:
-Preferred agent
-Maintenance therapy is recommended to prevent relapse.
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:
Acute therapy (induction): 12 mg/kg IV or orally on the first day followed by 10 to 12 mg/kg IV or orally once a day
Maximum dose: 800 mg/dose
Duration of therapy: At least 2 weeks
Consolidation therapy: 12 mg/kg IV or orally on the first day followed by 10 to 12 mg/kg IV or orally once a day
Maximum dose: 800 mg/dose
Duration of therapy: At least 8 weeks
Secondary prophylaxis: 6 mg/kg orally once a day
Maximum dose: 200 mg/dose
Duration of therapy: At least 1 year
Comments:
-Recommended in alternative regimens for acute therapy if flucytosine not tolerated or unavailable or amphotericin B-based therapy not tolerated
-Recommended as preferred agent for consolidation therapy; should be followed by secondary prophylaxis
-Recommended as preferred therapy for secondary prophylaxis
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents:
-Induction therapy: 400 to 1200 mg IV or orally once a day for at least 2 weeks
-Consolidation therapy (after at least 2 weeks successful induction therapy): 400 mg IV or orally once a day for at least 8 weeks
-Maintenance therapy: 200 mg orally once a day for at least 1 year
Comments:
-Recommended for use in alternative regimens for induction therapy; dose depends on regimen (i.e., used with amphotericin B, flucytosine, or alone).
-Recommended as preferred regimen for consolidation therapy; should be followed by maintenance therapy
-Recommended as preferred regimen for maintenance therapy
Usual Pediatric Dose for Cryptococcosis:
IDSA Recommendations for children:Disseminated disease:
-Consolidation therapy : 10 to 12 mg/kg/day orally in 2 divided doses for 8 weeks
-Maintenance therapy in HIV-infected patients: 6 mg/kg orally once a day
Cryptococcal pneumonia: 6 to 12 mg/kg orally once a day for 6 to 12 months
Comments:
-Preferred agent
-Maintenance therapy is recommended to prevent relapse.
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:
Localized disease (including isolated pulmonary disease [non-CNS]), disseminated disease (non-CNS), or severe pulmonary disease: 12 mg/kg IV or orally on the first day followed by 6 to 12 mg/kg IV or orally once a day
Maximum dose: 600 mg/dose
Duration of therapy: Based on site and severity of infection and clinical response
Secondary prophylaxis: 6 mg/kg orally once a day
Maximum dose: 200 mg/dose
Duration of therapy: At least 1 year
Comments:
-Recommended as preferred therapy for localized disease and secondary prophylaxis
-Recommended as alternative therapy for disseminated disease and severe pulmonary disease
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents:
Non-CNS cryptococcosis with mild to moderate symptoms and focal pulmonary infiltrates: 400 mg orally once a day for 12 months
Non-CNS, extrapulmonary cryptococcosis and diffuse pulmonary disease:
-Induction therapy: 400 to 1200 mg IV or orally once a day for at least 2 weeks
-Consolidation therapy (after at least 2 weeks successful induction therapy): 400 mg IV or orally once a day for at least 8 weeks
-Maintenance therapy: 200 mg orally once a day for at least 1 year
Comments:
-Recommended for use in alternative regimens for induction therapy; dose depends on regimen (i.e., used with amphotericin B, flucytosine, or alone).
-Recommended as preferred regimen for consolidation therapy; should be followed by maintenance therapy
-Recommended as preferred regimen for maintenance therapy
Usual Pediatric Dose for Fungal Infection Prophylaxis:
IDSA Recommendations:Empiric therapy for suspected candidiasis in nonneutropenic or neutropenic patients: 12 mg/kg IV or orally on the first day followed by 6 mg/kg IV or orally once a day
Duration of therapy:
-Nonneutropenic patients: Uncertain; should discontinue if cultures and/or serodiagnostic test results negative
Comments:
-Suspected candidiasis in nonneutropenic patients: Recommended as primary therapy; an echinocandin is preferred for moderately severe to severe illness or recent azole exposure; patient selection should be based on clinical risk factors, serologic tests, and culture data.
-Suspected candidiasis in neutropenic patients: Recommended as alternative therapy; should start empiric therapy after 4 days persistent fever despite antibiotics; serodiagnostic and CT imaging may help; should not use in patients with prior azole prophylaxis.
Usual Pediatric Dose for Candida Urinary Tract Infection:
IDSA Recommendations:-Asymptomatic cystitis in patients undergoing urologic procedures: 3 to 6 mg/kg IV or orally once a day for several days before and after the procedure
-Symptomatic cystitis: 3 mg/kg IV or orally once a day for 2 weeks
-Pyelonephritis: 3 to 6 mg/kg IV or orally once a day for 2 weeks
-Urinary Conarex balls: 3 to 6 mg/kg IV or orally once a day until symptoms resolve and urine cultures clear of Candida
Comments:
-Recommended as primary therapy
-The suggested dose for candidemia is recommended for patients with pyelonephritis and suspected disseminated candidiasis.
-Surgical removal of urinary Conarex balls strongly recommended in non-neonates.
Usual Pediatric Dose for Coccidioidomycosis -- Meningitis:
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:Meningeal infection: 12 mg/kg IV or orally once a day
Maximum dose: 800 mg/dose
Secondary prophylaxis: 6 mg/kg orally once a day
Maximum dose: 400 mg/dose
Duration of therapy: Lifelong
Comments:
-Recommended as preferred therapy
-Secondary prophylaxis should follow treatment of meningeal infection.
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents:
-Meningeal infection: 400 to 800 mg IV or orally once a day
-Chronic suppressive therapy: 400 mg orally once a day
Comments:
-Recommended as preferred therapy for meningeal infection and chronic suppressive therapy
-A specialist should be consulted for meningeal infections.
-Since relapse is common, suppressive therapy should be lifelong.
Usual Pediatric Dose for Coccidioidomycosis:
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:Severe illness with respiratory compromise due to diffuse pulmonary or disseminated nonmeningeal infection: 12 mg/kg IV or orally once a day
Maximum dose: 800 mg/dose
Duration of therapy: 1 year total
Mild to moderate nonmeningeal infection (e.g., focal pneumonia): 6 to 12 mg/kg IV or orally once a day
Maximum dose: 400 mg/dose
Secondary prophylaxis: 6 mg/kg orally once a day
Maximum dose: 400 mg/dose
Duration of therapy: Lifelong in patients with disseminated disease
Comments:
-Recommended as alternative therapy for severe illness with respiratory compromise due to diffuse pulmonary or disseminated nonmeningeal infection; should be followed by secondary prophylaxis
-After patient with severe illness with respiratory compromise due to diffuse pulmonary or disseminated nonmeningeal infection is stabilized using the preferred regimen, may switch to Conarex to complete therapy (total duration: 1 year)
-Recommended as preferred therapy for secondary prophylaxis; usually recommended after initial induction therapy for disseminated disease; may also be used after milder disease
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents:
-Primary prophylaxis: 400 mg orally once a day
-Mild infections (e.g., focal pneumonia): 400 mg orally once a day
-Severe nonmeningeal infection (diffuse pulmonary or severely ill patients with extrathoracic disseminated disease) - acute phase: 400 mg IV or orally once a day
-Chronic suppressive therapy (secondary prophylaxis): 400 mg orally once a day
Comments:
-Recommended as preferred therapy for mild infection and chronic suppressive therapy
-Recommended as alternative therapy for severe nonmeningeal infection; some experts add a triazole to amphotericin B (preferred therapy) and continue the triazole after amphotericin B is stopped.
Usual Pediatric Dose for Vaginal Candidiasis:
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents:-Uncomplicated vulvovaginal candidiasis: 150 mg orally as a single dose
-Severe or recurrent vulvovaginal candidiasis: 100 to 200 mg orally once a day for at least 7 days
-Suppressive therapy for vulvovaginal candidiasis: 150 mg orally once a week
Comments:
-Recommended as preferred therapy
-Unless frequent or severe recurrences, suppressive therapy generally not recommended
Usual Pediatric Dose for Histoplasmosis:
US CDC, NIH, IDSA, PIDS, and AAP Recommendations for HIV-exposed and HIV-infected Children:Acute primary pulmonary infection: 3 to 6 mg/kg orally once a day
Maximum dose: 200 mg/dose
Mild disseminated disease: 5 to 6 mg/kg IV or orally twice a day
Maximum dose: 300 mg/dose
Duration of therapy: 12 months
Secondary prophylaxis: 3 to 6 mg/kg orally once a day
Maximum dose: 200 mg/dose
Comments:
-Recommended as alternative therapy
US CDC, NIH, and IDSA Recommendations for HIV-infected Adolescents:
-Less severe disseminated infection: 800 mg orally once a day for at least 12 months
-Long-term suppressive therapy : 400 mg orally once a day for more than 1 year
Comments:
-Recommended as alternative therapy
-This drug should only be used for treatment of less severe disseminated infection in moderately ill patients intolerant of itraconazole.
Select the most affordable brand or generic drug
Generic drug is the basic drug with an active substance in it, and the name of the generic drug is same as active substance most of the times. Like Acetaminophen/Paracetemol is Generic name and it has different brand names like Tylenol, Acimol, Crocin, Calpol etc. All these Brand names contain the same Paracetemol, but the medications are manufactured by different companies, so the different brand names. Generic drug is always cheaper and affordable, and it can be replaced in place of brand name drug prescribed by the healthcare practitioner. The Generic medicine has same properties as branded medicine in terms of uses, indications, doses, side effects, so no need to worry on that. Just select the most affordable generic or branded medicine.